Hepatocellular carcinoma with portal vein tumor thrombosis, accompanied by abdominal pain and jaundice.
Conditions
Interventions
By Optical Visualization Navigation Group:Optical Visualization Navigation
By Hand Group:none
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1).Aged 18-80 years at the time of signing the informed consent form; (2).Patients with HCC confirmed by pathology or meeting clinical diagnostic criteria, who are not eligible for radical therapy and have experienced progression of newly developed portal vein tumor thrombus (PVTT) after over 6 months of first- or second-line treatment;clinical staging is CNLC IIIa with PVTT type I-II; (3) Performance Status (PS) score of 0-1;(4) Life expectancy > 3 months;(5)No significant liver function impairment (Child-Pugh class A or B, with a score 50,000/µL ;(8). Prothrombin time (PT) > 50% and activated partial thromboplastin time (APTT) < 50 seconds. If necessary, correct hemostatic function (e.g., administer platelet concentrate) and drain ascites prior to treatment;(9). Voluntary participation, good compliance, and cooperation with follow-up.
Exclusion criteria
Exclusion criteria: 1. No extrahepatic disease or progressive extrahepatic disease; patients with localized extrahepatic disease confined to a single organ system, with up to 3 lymph nodes (each with a short-axis diameter 50% of total liver volume, or patients who have previously undergone liver transplantation; 5. Patients with portal vein tumor thrombus who have previously received local radiotherapy or similar treatments; 6. Other factors which, in the investigator's judgment, may affect study outcomes and potentially compromise the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local tumor control rate;Progression-Free Survival (PFS);Overall Survival (OS); | — |
Countries
China
Contacts
Public ContactLu Liu
Lishui Central Hospital
Outcome results
None listed